#How Did China Make a Move in Brain-Computer Interfaces?
China recently made headlines by becoming the first country to approve a commercial brain-computer interface, or BCI. On March 13, 2026, the National Medical Products Administration granted permission to Neuracle Medical Technology to market its invasive BCI system, marking a significant achievement in neurotechnology. Unlike Neuralink, which is still in clinical trials, Neuracle has been given the go-ahead to sell an implantable BCI device to consumers.
#What Is the Function of the Neuracle Device?
The Neuracle implant, also known as NEO, is a disk-shaped device that is placed on the brain's surface. It has the capability to decode motor signals and convert them into commands that can operate assistive devices, such as robotic hands. While its approved application is limited to individuals aged 18 to 60 suffering from severe paralysis due to cervical spinal cord injuries, its potential impact is considerable.
#How Does Neuracle Differ from Other Technologies?
Notably, the placement of the Neuracle device sets it apart from other BCI technologies. It does not penetrate the brain tissue like some of its competitors. Instead, it resides on the cortical surface, potentially leading to fewer complications and simpler procedures for implantation.
#What Competition Exists in the BCI Space?
While Neuracle has achieved commercial approval, another Shanghai-based company, NeuroXess, is also advancing rapidly in this field. NeuroXess is currently running a year-long clinical trial with a paralyzed patient. Their ambitious project follows a milestone in late 2025, when they successfully implanted China’s first fully wireless and battery-integrated BCI. This “triple-full” system is fully implanted, fully wireless, and fully battery-operated, setting high standards for future neurotechnology developments.
#Why Is China Leading in BCI Development?
China is strategically positioning itself as a leader in the BCI market. The country has classified brain-computer interfaces as a key emerging industry in its policy framework, receiving backing from initiatives such as the 13th Five-Year Plan. New directives released in December 2025 further emphasize the government's commitment to accelerating the sector. With the BCI market in China valued at around RMB 3.2 billion, or roughly $446 million in 2024, the landscape for investors looks promising as Neuracle's device becomes available for sale.
#What Should Investors Keep in Mind?
Investors should be aware that neither Neuracle nor NeuroXess is involved in the cryptocurrency market or blockchain technology. This absence of digital tokens or decentralized science protocols means that potential investors should focus instead on the implications of post-market surveillance data from Neuracle’s commercial operations and NeuroXess’s clinical trial results. These insights will be crucial in determining the maturation speed of this burgeoning market.